Last reviewed · How we verify
Aprepitant vs. Gabapentin
Aprepitant is a substance P/neurokinin 1 (NK1) receptor antagonist, which blocks the action of substance P, a natural substance in the body that causes nausea and vomiting.
Aprepitant is a substance P/neurokinin 1 (NK1) receptor antagonist, which blocks the action of substance P, a natural substance in the body that causes nausea and vomiting. Used for Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV), Postoperative nausea and vomiting (PONV).
At a glance
| Generic name | Aprepitant vs. Gabapentin |
|---|---|
| Sponsor | New Mexico Cancer Research Alliance |
| Drug class | NK1 receptor antagonist |
| Target | NK1 receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Substance P/neurokinin 1 (NK1) receptors are found in the central nervous system and are involved in the transmission of pain and nausea signals. By blocking these receptors, aprepitant reduces the incidence of chemotherapy-induced nausea and vomiting.
Approved indications
- Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
- Postoperative nausea and vomiting (PONV)
Common side effects
- Headache
- Nausea
- Diarrhea
- Fatigue
Key clinical trials
- Comparison of Aprepitant Versus Gabapentin in the Prevention of Delayed Nausea and Vomiting (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aprepitant vs. Gabapentin CI brief — competitive landscape report
- Aprepitant vs. Gabapentin updates RSS · CI watch RSS
- New Mexico Cancer Research Alliance portfolio CI